# Wondercel Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wondercel-therapeutics

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.wondercel.com
- Total disclosed funding: $35M
- Latest round: Series A (Jul 10, 2026)
- Investors on record: 3

## About

Based in Shenzhen, China, and founded in 2022, Shenzhen Bay Island Cell Technology Co., Ltd., trading as Wondercel Therapeutics, is a cell and gene therapy developer dedicated to exploring solutions to the shortcomings of existing cell drugs and developing safer and more economical next-generation immune cell therapy technologies to unleash the unlimited potential of human immune cells in the treatment of tumors, organ transplantation, and autoimmune diseases.
In July 2026, Wondercel Therapeutics raised CNY 140 million in series A funding led by Green Pine Capital Partners, with participation from Oriental Fortune Capital.
Wondercel Therapeutics specializes in the development of advanced cellular therapies aimed at addressing a variety of chronic health conditions. Their core product offerings include proprietary solutions that leverage stem cell technology, specifically designed to regenerate damaged tissues and enhance overall cellular function. These products target conditions such as degenerative diseases, wound healing, and age-related ailments, effectively providing patients with alternatives to traditional treatment methods. The company serves a diverse client base, including hospitals, specialized clinics, and healthcare providers primarily located in North America and Europe, where they have strategically positioned their therapies to meet the growing demand for innovative healthcare solutions.
Wondercel Therapeutics generates revenue primarily through a combination of direct-to-consumer sales and partnerships with healthcare providers. The company has established a structured pricing model for its flagship therapeutic products, which may involve both one-time purchases and subscription services for ongoing treatment plans. Transactions typically occur through healthcare facilities that integrate Wondercel’s therapies into their treatment offerings, facilitating access for patients in need. The revenue model is designed to accommodate different client needs, thus allowing flexibility in how these therapies are accessed while ensuring consistent company growth through strategic collaborations and distribution agreements.
The series A round of financing will provide the necessary resources for the upcoming clinical trials. Wondercel Therapeutics aims to develop revolutionary cell therapy products for cancer and other serious diseases by advancing technological breakthroughs in cell therapy and providing patients with more effective treatment options.

## Funding rounds

- Series A, Jul 10, 2026, $21M — Oriental Fortune Capital, Green Pine Capital Partners
- Angel, Feb 10, 2023, $15M — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A